UK Cardiovascular Diseases Therapeutics Market Analysis

UK Cardiovascular Diseases Therapeutics Market Analysis


$ 3999

UK's cardiovascular disease therapeutics market is projected to grow from $4.22 Bn in 2022 to $6.35 Bn in 2030 with a CAGR of 5.22% for the year 2022-30. Cardiovascular disease remains the major cause of death in the UK, also the development of new drugs for the treatment of cardiovascular diseases in the UK is the major growth driver of the market. The UK cardiovascular disease therapeutics market is segmented by disease indication, drug type, route of administration, drug classification, mode of purchase, and by end user. Ackerley Pharma, eXmoor Pharma, and Bristol-Myers Squibb are the major players in the UK cardiovascular disease therapeutics market.

ID: IN10GBPH033 CATEGORY: Pharmaceuticals GEOGRAPHY: UK AUTHOR: Parul Choudhary

Buy Now

UK Cardiovascular Disease Therapeutics Market Executive Analysis

UK's cardiovascular disease therapeutics market is projected to grow from $4.22 Bn in 2022 to $6.35 Bn in 2030 with a CAGR of 5.22% for the year 2022-30. The Chancellor pledged an additional $3.53 Bn for the National Health Service (NHS) in the 2022 Autumn Statement, as well as £1.4 Bn for capital expenditures in 2023-24 and 2024-25. Spending in 2024-25 will be nearly $15 Bn more than in 2022-23 in terms of money. As a result, core annual day-to-day NHS spending will increase by 2% by 2024-25 while capital spending will only expand by 0.2%. Over the next two years, the budget settlement for the Department of Health and Social Care will rise overall by 1.2% a year in real terms. This is more than what was anticipated in the previous spending review, but it is still much lower than the long-term average increase rate of 3.6%.

Despite decades of advancements in research, better treatments, and initiatives to raise public awareness of lifestyle risk factors that can contribute to the development of some cardiovascular diseases (CVD), CVD continues to be the top cause of mortality in the UK. Morbidity-wise, CVD continues to be a major burden in the UK, causing at least 1.18 Mn hospital admissions and reflecting the CVD's enormous economic burden, which is assessed to be $20 Bn in the country.

Inclisiran, a cholesterol-lowering medication that has not yet received FDA approval, will be tested on patients in the UK as part of a significant NHS clinical study that is anticipated to begin later this year. Additionally, in a first for the world, the drug is anticipated to be made accessible via a population-level agreement, ushering in a revolutionary method of lowering the risk of heart disease. Over three Mn people have atherosclerotic cardiovascular disease, and 2.5 Mn of them presently take statins to reduce their cholesterol. Heart disease is the second leading cause of death in the UK and the leading cause of death globally. In just two weeks, inclisiran can reduce bad LDL by half, according to recent studies. This emphasizes the UK is a top location to deliver novel medications to patients more quickly and affordably. Similar agreements could be made for other large-scale drug development initiatives thanks to its appetite for innovation, unmatched infrastructure, and the world-class integrated healthcare system.

uk cardiovascular disease therapeutics market analysis

Market Dynamics

Market Growth Drivers

The majority of deaths in the UK are caused by cardiovascular diseases (CVD), which account for nearly one-third of all fatalities. Due to factors like an aging population and an increase in risk factors like obesity, diabetes, and high blood pressure, it is anticipated that the frequency of CVD will rise in the upcoming years. The cardiovascular disease therapeutics market is anticipated to increase as a result. Pharmaceutical firms are making significant investments in the study and development of novel treatments for cardiovascular disease. As a result, both novel drugs are currently being developed and existing drugs are being improved. For instance, the creation of PCSK9 inhibitors, a new kind of cholesterol-lowering drug, can completely alter the way cardiovascular disease is treated.

Market Restraints

It is expensive and time-consuming to develop novel treatments for cardiovascular disease. A lack of funding for drug development on the part of smaller pharmaceutical firms may reduce the number of drugs that are available on the market. High drug prices may restrict patients' access to some treatments as a result of high drug development expenses. Existing therapies for cardiovascular illness see the availability of generic versions as their patents expire. Price competition and decreased revenue for the pharmaceutical companies that produced the initial drugs can result from this thereby limiting the expansion of the UK cardiovascular disease therapeutics market.

Competitive Landscape

Key Players

  • Kliklok International (GBR)
  • Bioventus Pharmaceuticals (GBR)
  • Pharma Medico (GBR)
  • Ackerley Pharma (GBR)
  • eXmoor Pharma (GBR)
  • Bristol-Myers Squibb
  • Pfizer
  • Bayer
  • Janssen Pharmaceuticals
  • AstraZeneca
  • Sanofi
  • Novartis

Healthcare Policies and Regulatory Landscape

The National Health Service (NHS), which is publicly financed and offers healthcare free of charge to UK citizens, is in charge of providing healthcare in the country. The diagnosis and treatment of cardiovascular disease (CVD) are among the medical treatments covered by the NHS. The National Institute for Health and Care Excellence (NICE) has established a set of rules that the NHS must abide by when it comes to paying for CVD therapies. NICE offers recommendations for the best and most affordable treatments for a range of medical problems, including CVD. The NHS uses these standards to determine which treatments to fund and reimburse. For example, NICE advises that patients who have a high chance of developing CVD be offered statins, which are medications used to lower cholesterol levels. Therefore, for those who qualify, the NHS will pay for the expense of statins. The NHS also provides a variety of surgical and non-surgical treatments for CVD, such as coronary artery bypass surgery and angioplasty, in addition to drug therapies. In the UK, private health insurance is also an option, and some policies might pay for CVD treatments not covered by the NHS. Private health insurance, on the other hand, is frequently more costly than using the NHS and might not be available to all patients.

1. Executive Summary
1.1 Disease Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Patient Journey
1.6 Health Insurance Coverage in Country
1.7 Active Pharmaceutical Ingredient (API)
1.8 Recent Developments in the Country

2. Market Size and Forecasting
2.1 Epidemiology of Disease
2.2 Market Size (With Excel & Methodology)
2.3 Market Segmentation (Check all Segments in Segmentation Section)

3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints

4. Competitive Landscape
4.1 Major Market Share

4.2 Key Company Profile (Check all Companies in the Summary Section)

4.2.1 Company
4.2.1.1 Overview
4.2.1.2 Product Applications and Services
4.2.1.3 Recent Developments
4.2.1.4 Partnerships Ecosystem
4.2.1.5 Financials (Based on Availability)

5. Reimbursement Scenario
5.1 Reimbursement Regulation
5.2 Reimbursement Process for Diagnosis
5.3 Reimbursement Process for Treatment

6. Methodology and Scope

UK Cardiovascular Disease Therapeutics Segmentation

By Disease Indication (Revenue, USD Billion):

  • Hypertension
  • Coronary Artery Disease
  • Hyperlipidaemia
  • Arrhythmia
  • Others

By Drug Type (Revenue, USD Billion):

  • Antihypertensive
  • Anticoagulants
  • Antihyperlipidemic
  • Antiplatelet Drugs
  • Others

By Route of Administration (Revenue, USD Billion):

  • Oral
  • Parenteral
  • Others

By Drug Classification (Revenue, USD Billion):

  • Branded Drugs
  • Generic Drugs

By Mode of Purchase (Revenue, USD Billion):

  • Prescription-Based Drugs
  • Over-The-Counter Drugs

By End Users (Revenue, USD Billion):

  • Hospital Pharmacies
  • Online Pharmacies
  • Retail Pharmacies
  • Others

Insights10 will provide you with the reports within 10 key parameters which are:

  1. Market Overview
  2. Market Growth Drivers & Restraints
  3. Epidemiology of Disease Type
  4. Market Segmentation
  5. Market Share
  6. Competitive Landscape
  7. Key Company Profiles
  8. Healthcare Policies & Regulatory Framework
  9. Reimbursement Scenario
  10. Factors Driving Future Growth

Based on our many years of experience, we believe that these are the parameters that are critical to decision-making for business stakeholders. Our focused approach to developing reports focused on 10 key parameters, enabled us to arrive at the name “Insights10”.

 

Stage I: Market Data Collection

Primary Interviews: We have developed a network of experts, freelancers, and researchers across countries through which we engage with local experts to gather key data points and assumptions about each market. We also engage regularly with some of the best market research agencies such as Atheneum, GuidePoint, GLG, etc. to conduct surveys and interviews, and build intelligence. We have language translators as a part of our team, who between them can cover 30+ languages allowing us to extract better local insights.

Secondary Data Collection: We have developed strong expertise and experience in secondary data collection methods for developing unique data sets and research material. We gather data from multiple reliable sources to maintain a high level of accuracy and consistency. The market data is analyzed and forecasted using appropriate statistical and coherent models. The report offers an overall analysis of the market size, growth, and market share as well as a segment-level analysis of the specific market. Our report includes precise, to-the-point information related to the overall market, competition, growth drivers, challenges, regulatory updates, and competition.

Data Sources: We have access to multiple highly reliable free and subscription data sources. We have many years of experience to understand which sources are more dependable for what and which to prefer for the reliable and latest information. The key sources of information include the following, but are not limited to:

 

 

Stage II: Market Data Analysis and Statistical Model

Market Trends: We generally look at macro parameters and micro indicators. The macro parameters include changes in government policies, demand and supply of the market, government intervention programs, and major market share. The micro indicators are GDP growth, market size, market volume, etc. We also understand nuances specific to each country like the US, Canada, India, Germany, etc., and have worked across 60+ countries and hence not only understand global trends but how these differ by country, how payment models, market structure, cultural parameters, etc. differ in each country.

Market Sizing and Analysis: Our expert data analytics team has created various market forecast models by employing the top-down approach i.e. starting with the large overall market and segmenting different areas and the bottom-up approach i.e. starting with population and epidemiology and rolling up based on spend, etc., estimating the size of the market, and distributing among the geographic and/or product segments.

The top-down approach is mainly used for new product forecasting and the bottom-up approach is used for demand estimation of any product for different countries summed up to form the total market. We are able to round off insights and build stronger forecasts because we always do both these methods and triangulate the final numbers.

The study on the market covers the analysis of the leading geographies such as Asia-Pacific, Africa, Europe, Middle East, North America, and  Latin America for the period of 2022 to 2030. The qualitative analysis covers the industry landscape and trends, market opportunities, competitive landscape, and policy and regulatory scenario, and the quantitative analysis covers different market estimates and forecasts.

Data Triangulation & Validation:

Data triangulation of various sources and results of the research are carried out by benchmarking with reliable sources such as industry statistics, statistical databases, and company-level averages, etc.

We make sure to finalize the numbers in alignment with the market research. Firstly, our internal experts ensure thorough validation and checking to ensure accurate and precise analysis and then validation is also done using a multiple-data analysis model. Two-level validation is done and entails the finalization of the report scope and the way of representation pattern.

 

 

Stage III: Interpretation and Presentation

Analysis & Interpretation: The information gathered is then analyzed and synthesized. The second series of interviews are done if necessary to check and validate. The future opportunities are analyzed by understanding product commercialization and many other factors. It also comprises the analysis of data discrepancies observed across various data sources. Information procured from secondary and primary results is then, interpreted by considering the following parameters: (a partial list)

  • Establishing market drivers and trends
  • Analyzing the regulatory landscape to understand future growth
  • Market Segment based analysis to obtain revenue/volume
  • ​Analyzing current needs and determining penetration to estimate the market

Insights: Our reports deliver actionable insights backed with supporting facts and figures to assist you in achieving exemplary growth. Our in-depth analyses are interspersed with relevant insights and statistics to offer an executive-level view of a given market. The description helps in correlating many minor factors affecting the market and their impact on the different segments within the market.

Data curated from the analysis and interpretation are drawn to portray all in one consolidated report.

Presentation & Reporting: The market research report is presented in different forms such as charts by using a scientific approach for easy understanding. Historic, current, and future analysis is provided for each market in terms of both value and volume. The size of the market is interpreted in the US Dollar value and the respective unit, based on the product, for volume consumption.

The foreign exchange rates are calculated on the respective dates and for the respective regions covered in the study.

To request a free sample copy of this report, please complete the form below.


We value your inquiry and offer free customization with every report to fulfil your exact research needs.


This report addresses

  • Intelligent insights to take informed business decisions
  • Qualitative, acute and result oriented market analysis
  • Market size and forecasts from 2022 to 2030
  • Opportunities for expansion and in-depth market analysis
  • Segmentation and regional revenue forecasts
  • Analysis of the market share and competitive landscape
  • Strategic Recommendations to chart future course of action
  • Comprehensive Market Research Report in PDF and PPT formats

Need more?

  • Ask our analyst how this study was put together to learn more
  • Discuss additional requirements as part of the free customisation
  • Add more countries or regions to the scope 
  • Get answers to specific business questions 
  • Develop the business case to launch the product
  • Find out how this report may influence your business revenue
Last updated on: 14 February 2024
Updated by: Dhruv Joshi

Related reports (by category)


Related reports (by geography)


subscribe to our newsletter
up